297 related articles for article (PubMed ID: 27026610)
21. Cancer driver drug interaction explorer.
Hartung M; Anastasi E; Mamdouh ZM; Nogales C; Schmidt HHHW; Baumbach J; Zolotareva O; List M
Nucleic Acids Res; 2022 Jul; 50(W1):W138-W144. PubMed ID: 35580047
[TBL] [Abstract][Full Text] [Related]
22. Guiding Drug Repositioning for Cancers Based on Drug Similarity Networks.
Qin S; Li W; Yu H; Xu M; Li C; Fu L; Sun S; He Y; Lv J; He W; Chen L
Int J Mol Sci; 2023 Jan; 24(3):. PubMed ID: 36768566
[TBL] [Abstract][Full Text] [Related]
23. PanDrugs: a novel method to prioritize anticancer drug treatments according to individual genomic data.
Piñeiro-Yáñez E; Reboiro-Jato M; Gómez-López G; Perales-Patón J; Troulé K; Rodríguez JM; Tejero H; Shimamura T; López-Casas PP; Carretero J; Valencia A; Hidalgo M; Glez-Peña D; Al-Shahrour F
Genome Med; 2018 May; 10(1):41. PubMed ID: 29848362
[TBL] [Abstract][Full Text] [Related]
24. A bioinformatics approach for precision medicine off-label drug drug selection among triple negative breast cancer patients.
Cheng L; Schneider BP; Li L
J Am Med Inform Assoc; 2016 Jul; 23(4):741-9. PubMed ID: 27107440
[TBL] [Abstract][Full Text] [Related]
25. Drug repositioning in head and neck squamous cell carcinoma: An integrated pathway analysis based on connectivity map and differential gene expression.
Wei GG; Gao L; Tang ZY; Lin P; Liang LB; Zeng JJ; Chen G; Zhang LC
Pathol Res Pract; 2019 Jun; 215(6):152378. PubMed ID: 30871913
[TBL] [Abstract][Full Text] [Related]
26. In silico prescription of anticancer drugs to cohorts of 28 tumor types reveals targeting opportunities.
Rubio-Perez C; Tamborero D; Schroeder MP; Antolín AA; Deu-Pons J; Perez-Llamas C; Mestres J; Gonzalez-Perez A; Lopez-Bigas N
Cancer Cell; 2015 Mar; 27(3):382-96. PubMed ID: 25759023
[TBL] [Abstract][Full Text] [Related]
27. Inferring new indications for approved drugs via random walk on drug-disease heterogenous networks.
Liu H; Song Y; Guan J; Luo L; Zhuang Z
BMC Bioinformatics; 2016 Dec; 17(Suppl 17):539. PubMed ID: 28155639
[TBL] [Abstract][Full Text] [Related]
28. Characterizing genomic differences of human cancer stratified by the TP53 mutation status.
Wang M; Yang C; Zhang X; Li X
Mol Genet Genomics; 2018 Jun; 293(3):737-746. PubMed ID: 29330617
[TBL] [Abstract][Full Text] [Related]
29. The use of PanDrugs to prioritize anticancer drug treatments in a case of T-ALL based on individual genomic data.
Fernández-Navarro P; López-Nieva P; Piñeiro-Yañez E; Carreño-Tarragona G; Martinez-López J; Sánchez Pérez R; Aroca Á; Al-Shahrour F; Cobos-Fernández MÁ; Fernández-Piqueras J
BMC Cancer; 2019 Oct; 19(1):1005. PubMed ID: 31655559
[TBL] [Abstract][Full Text] [Related]
30. TQuest, A Web-Based Platform to Enable Precision Medicine by Linking a Tumor's Genetic Defects to Therapeutic Options.
Gershkovich P; Platt J; Knopf J; Tasoulis MK; Shi W; Pusztai L; Hatzis C
JCO Clin Cancer Inform; 2018 Dec; 2():1-13. PubMed ID: 30652574
[TBL] [Abstract][Full Text] [Related]
31. Molecular Network-Based Drug Prediction in Thyroid Cancer.
Xu X; Long H; Xi B; Ji B; Li Z; Dang Y; Jiang C; Yao Y; Yang J
Int J Mol Sci; 2019 Jan; 20(2):. PubMed ID: 30641858
[TBL] [Abstract][Full Text] [Related]
32. Quantitative and Systems Pharmacology. 1. In Silico Prediction of Drug-Target Interactions of Natural Products Enables New Targeted Cancer Therapy.
Fang J; Wu Z; Cai C; Wang Q; Tang Y; Cheng F
J Chem Inf Model; 2017 Nov; 57(11):2657-2671. PubMed ID: 28956927
[TBL] [Abstract][Full Text] [Related]
33. The Drug Rediscovery protocol facilitates the expanded use of existing anticancer drugs.
van der Velden DL; Hoes LR; van der Wijngaart H; van Berge Henegouwen JM; van Werkhoven E; Roepman P; Schilsky RL; de Leng WWJ; Huitema ADR; Nuijen B; Nederlof PM; van Herpen CML; de Groot DJA; Devriese LA; Hoeben A; de Jonge MJA; Chalabi M; Smit EF; de Langen AJ; Mehra N; Labots M; Kapiteijn E; Sleijfer S; Cuppen E; Verheul HMW; Gelderblom H; Voest EE
Nature; 2019 Oct; 574(7776):127-131. PubMed ID: 31570881
[TBL] [Abstract][Full Text] [Related]
34. RefDNN: a reference drug based neural network for more accurate prediction of anticancer drug resistance.
Choi J; Park S; Ahn J
Sci Rep; 2020 Feb; 10(1):1861. PubMed ID: 32024872
[TBL] [Abstract][Full Text] [Related]
35. Can Drug Repurposing Accelerate Precision Oncology?
Schipper LJ; Zeverijn LJ; Garnett MJ; Voest EE
Cancer Discov; 2022 Jul; 12(7):1634-1641. PubMed ID: 35642948
[TBL] [Abstract][Full Text] [Related]
36. Hotspot mutations delineating diverse mutational signatures and biological utilities across cancer types.
Chen T; Wang Z; Zhou W; Chong Z; Meric-Bernstam F; Mills GB; Chen K
BMC Genomics; 2016 Jun; 17 Suppl 2(Suppl 2):394. PubMed ID: 27356755
[TBL] [Abstract][Full Text] [Related]
37. Using Prognosis-Related Gene Expression Signature and Connectivity Map for Personalized Drug Repositioning in Multiple Myeloma.
Zhu FX; He YC; Zhang JY; Wang HF; Zhong C; Wang XT
Med Sci Monit; 2019 May; 25():3247-3255. PubMed ID: 31048671
[TBL] [Abstract][Full Text] [Related]
38. Targeting Cancer Stem Cells with Repurposed Drugs to Improve Current Therapies.
Fong D; Christensen CT; Chan MM
Recent Pat Anticancer Drug Discov; 2021; 16(2):136-160. PubMed ID: 33563159
[TBL] [Abstract][Full Text] [Related]
39. Structure-based drug repositioning: Potential and limits.
Adasme MF; Parisi D; Sveshnikova A; Schroeder M
Semin Cancer Biol; 2021 Jan; 68():192-198. PubMed ID: 32032699
[TBL] [Abstract][Full Text] [Related]
40. Comprehensive review of the repositioning of non-oncologic drugs for cancer immunotherapy.
Rauf A; Joshi PB; Olatunde A; Hafeez N; Ahmad Z; Hemeg HA; Aljohani ASM; Al Abdulmonem W; Thiruvengadam M; Viswanathan D; Rajakumar G; Thiruvengadam R
Med Oncol; 2024 Apr; 41(5):122. PubMed ID: 38652344
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
